Alcohol-Based Hand Sanitizer-FDA Takes Action to Protect Public Health; Increase Supply of

Alcohol-Based Hand Sanitizer: The FDA has taken additional action to help ensure widespread access to hand sanitizers during the COVID-19 public health emergency.

Consumer and health care personnel safety is a top priority for FDA, and an important part of FDA’s mission is to protect the public from harm, including as the FDA seek to increase supply of hand sanitizer. The FDA has updated their guidances to provide additional clarification on the manufacturing and compounding of certain alcohol-based hand sanitizer products to help ensure that harmful levels of impurities are not present in ethanol used in hand sanitizer.

The FDA appreciates industry’s willingness to help meet the increasing demand for alcohol-based hand sanitizers during the COVID-19 pandemic. Early on during the public health emergency, as demand for alcohol-based hand sanitizer had dramatically increased, they issued temporary policies to provide flexibility to help meet this demand and to help get supply quickly to where it was needed, whether it was for health care professionals or for individuals and their families.

Although it is the FDA’s understanding that some larger hospital systems have been able to replenish their supply of hand sanitizer, they continue to hear that some smaller hospital systems and outpatient facilities are still experiencing difficulties accessing alcohol-based hand sanitizers. The FDA also recognizes that some consumers may not be able to find alcohol-based hand sanitizer in their local area, and, when they do, it is in limited quantities.  Washing our hands with soap and water, for at least 20 seconds, continues to be one of our best defenses to prevent the spread of COVID-19. If soap and water are not readily available, the Centers for Disease Control and Prevention (CDC) recommends consumers use an alcohol-based hand sanitizer that contains at least 60 percent alcohol (also referred to as ethanol or ethyl alcohol).

The FDA previously updated these temporary guidances in April to reflect data submitted by fuel ethanol manufacturers producing ethanol via fermentation and distillation, indicating that at least some of their fuel ethanol products have harmful chemicals, including gasoline and benzene, which are known human carcinogens (cancer-causing agents). These impurities would not be expected from a typical fermentation and distillation process but may be present in the manufacturing environment of fuel or technical-grade ethanol, due to the use of certain chemicals, equipment or containers.

The FDA is working with industry to ensure that harmful levels of impurities are not present if ethanol is used in these products. Based on careful review and consideration of available data, the FDA are specifying interim levels of certain impurities that they have determined can be tolerated for a relatively short period of time, given the emphasis on hand hygiene during the COVID-19 public health emergency and to avoid exacerbating access issues for alcohol-based hand sanitizer.

As with everything the FDA does, they are committed to ensuring that they appropriately balance risk and benefit. The FDA believes that our temporary guidances sets the proper level of flexibility at the current time to help protect Americans during this public health emergency. The FDA does not make any decision lightly and are continually assessing the needs and circumstances related to our temporary policies and how best to protect  public health. As relevant needs and circumstances evolve, the FDA intends to update, modify or withdraw these policies as appropriate.

Consumers, manufacturers or distributors who have questions for the FDA regarding hand sanitizers should email COVID-19-Hand-Sanitizers@fda.hhs.gov or visit the Frequently Asked Questions on Hand Sanitizer on the FDA’s website. As increased hand sanitizer supply becomes available, consumers are reminded to keep hand sanitizers out of the reach of children (who may swallow hand sanitizers, particularly if they are scented, brightly colored or attractively packaged) and, in case of ingestion, to get medical help or contact a Poison Control CenterExternal Link Disclaimer immediately. Very small amounts of hand sanitizer can be toxic, even lethal, to young children. Therefore, it is advisable that children should use such sanitizers with adult supervision.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.